Analyst consensus rating
Avalyn Pharma Analyst Rating: Strong Buy
AVLN is rated Strong Buy by 4 analysts with a $62.25 target. As of 2026-08-29.
Direct answer
Avalyn Pharma's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $62.25.
Forecast evidence checked August 29, 2026.
Get free Avalyn Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $34.69
- Average price target
- $62.25
- High price target
- $80.00
- Low price target
- $52.00
- Low target gap
- +49.9%
- Target upside
- +79.4%
- High target gap
- +130.6%
- Target range width
- 80.7%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Avalyn Pharma?
Avalyn Pharma has a verified Strong Buy consensus. The same dataset has an average price target of $62.25.
How far are Avalyn Pharma's low and high targets from the recorded price?
The low target implies +49.9%, while the high target implies +130.6%.
How many analysts are included in Avalyn Pharma's consensus?
The verified consensus includes 4 analysts.
How is Avalyn Pharma's target upside or downside calculated?
The average target of $62.25 is divided by the recorded price of $34.69, then one is subtracted to produce +79.4%. This does not guarantee a future return.
When was Avalyn Pharma's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.